These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33119804)

  • 1. Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy.
    van Rijssen TJ; van Dijk EHC; Scholz P; MacLaren RE; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):905-910. PubMed ID: 33119804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
    Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study.
    Pinto C; Sousa K; Oliveira E; Mendonça L; Gentil R; Queirós L; Falcão M
    Semin Ophthalmol; 2022 Feb; 37(2):153-157. PubMed ID: 34027797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
    Breukink MB; Mohabati D; van Dijk EH; den Hollander AI; de Jong EK; Dijkman G; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
    van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RETROSPECTIVE ANALYSIS OF THE PRESENCE OF CHOROIDAL NEOVASCULARISATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY WITH THE AID OF PHOTODYNAMIC THERAPY.
    Myslík Manethová K; Ernest J
    Cesk Slov Oftalmol; 2021; 77(3):122-131. PubMed ID: 35130703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
    van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
    Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.